注射用血塞通联合注射用脑蛋白水解物(Ⅲ)治疗后循环缺血性眩晕的临床研究

Clinical Study on the Treatment of Posterior Circulation Ischemic Vertigo with Xuesaitong Injection Combined with Cerebroprotein Hydrolysate for Injection(Ⅲ)

目的 探究采用注射用血塞通联合注射用脑蛋白水解物(Ⅲ)治疗后循环缺血性眩晕患者的疗效。方法 将2022年1月至2023年12月江苏省常州市武进中医医院86例后循环缺血性眩晕患者,通过信封抽签法分为对照组[注射用脑蛋白水解物(Ⅲ)治疗]和观察组(对照组基础上联合注射用血塞通治疗),每组43例。观察2组患者的疗效、血液流变学、脑血流量、血清细胞因子及药物不良反应。结果 观察组疗效优于对照组(93.02%vs 72.09%)(P <0.05)。2组治疗后椎-基底动脉和左、右侧椎动脉的脑血流速度、血清降钙素基因相关肽水平较本组治疗前升高(P <0.05),血浆黏度、全血黏度、血小板黏附率水平、内皮素-1较本组治疗前降低(P <0.05),且观察组改善程度优于对照组(P <0.05)。2组不良反应发生率比较差异无统计学意义(P> 0.05)。结论 采用注射用血塞通联合注射用脑蛋白水解物(Ⅲ)治疗后循环缺血性眩晕患者疗效较好,其作用机制可能与促进血流恢复,改善血管内皮损伤有关。

Objective To explore the therapeutic effect of Xuesaitong for injection combined with cerebroprotein hydrolysate for injection(Ⅲ)on patients with posterior circulation ischemic vertigo.Methods 86 patients with posterior circulation ischemic vertigo were randomly divided into a control group(n=43,treated with cerebroprotein hydrolysate for injection(Ⅲ))and an observation group(n=43,treated with Xuesaitong injection in addition to the control group)using the envelope drawing method.The efficacy,blood rheology,cerebral blood flow,serum cytokines,and adverse drug reactions were compared between the two groups.Results The therapeutic effect of the observation group was better than that of the control group(93.02%vs.72.09%)(P<0.05).After treatment,the cerebral blood flow velocity of the vertebrobasilar artery,left and right vertebral arteries,and serum calcitonin gene-related peptide levels were higher than those before treatment(P<0.05),and the plasma viscosity,whole blood viscosity,platelet adhesion rate,and endothelin-1 levels were lower than those before treatment(P<0.05).The improvement in the observation group was better than that in the control group(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion The combination of Xuesaitong injection and cerebroprotein hydrolysate for injection(Ⅲ)has a better therapeutic effect on patients with posterior circulation ischemic vertigo,which may be related to promoting blood flow recovery and improving vascular endothelial injury.